ATLANTA, GA – – (Globe Newswire – April 2, 2024) – – Holzer & Holzer, LLC is investigating whether Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA) complied with federal securities laws. On March 28, 2024, Zevra disclosed that it had “concluded that the Company’s previously issued audited consolidated financial statements as of and for the fiscal years ended December 31, 2022 and December 31, 2021, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, (collectively, the “Prior Financial Statements”) should no longer be relied upon.” Following this news, the price of the Company’s stock dropped.

If you purchased Zevra stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/zevra/ to discuss your legal rights.